164 related articles for article (PubMed ID: 24556169)
1. [Epidemiology of parkinsonism in the Guadalajara Health Area].
Martínez-Pérez JA; Ortiz-García R; González-Zerega A; López-Gosling I; Guzmán A; Dragomir E
Semergen; 2014 Sep; 40(6):305-12. PubMed ID: 24556169
[TBL] [Abstract][Full Text] [Related]
2. Cross-sectional survey of Parkinson's disease and parkinsonism in a rural area of the United Kingdom.
Hobson P; Gallacher J; Meara J
Mov Disord; 2005 Aug; 20(8):995-8. PubMed ID: 15852368
[TBL] [Abstract][Full Text] [Related]
3. [The prevalence and pharmacological cost of Parkinson's disease in Spain].
Abasolo-Osinaga E; Abecia-Inchaurregui LC; Fernández-Díaz E; Barcenilla-Laguna A; Bañares-Onraita T
Rev Neurol; 2006 Dec 1-15; 43(11):641-5. PubMed ID: 17133323
[TBL] [Abstract][Full Text] [Related]
4. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
Maurel F; Lilliu H; Le Pen C
Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
[TBL] [Abstract][Full Text] [Related]
5. Prescribing patterns of antiparkinson drugs in a group of Colombian patients, 2015.
Machado-Alba JE; Calvo-Torres LF; Gaviria-Mendoza A; Castrillón-Spitia JD
Biomedica; 2018 Sep; 38(3):417-426. PubMed ID: 30335247
[TBL] [Abstract][Full Text] [Related]
6. Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study.
Winter Y; von Campenhausen S; Reese JP; Balzer-Geldsetzer M; Longo K; Spiga G; Boetzel K; Eggert K; Oertel WH; Dodel R; Barone P
Neurodegener Dis; 2010; 7(6):365-72. PubMed ID: 20523028
[TBL] [Abstract][Full Text] [Related]
7. [Estimation of the prevalence of Parkinson's disease in Asturia, Spain. A pharmacoepidemiological study of the consumption of antiparkinson drugs].
Martínez-Suárez MM; Blázquez-Menes B
Rev Neurol; 2000 Dec 1-15; 31(11):1001-6. PubMed ID: 11190861
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Parkinson's disease in Spain.
Grandas F; Kulisevsky J
Mov Disord; 2003 Jan; 18(1):87-9. PubMed ID: 12518304
[TBL] [Abstract][Full Text] [Related]
9. Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London.
Schrag A; Ben-Shlomo Y; Quinn NP
BMJ; 2000 Jul; 321(7252):21-2. PubMed ID: 10875828
[No Abstract] [Full Text] [Related]
10. The prevalence of Parkinson's disease in an area of North Tyneside in the North-East of England.
Porter B; Macfarlane R; Unwin N; Walker R
Neuroepidemiology; 2006; 26(3):156-61. PubMed ID: 16493203
[TBL] [Abstract][Full Text] [Related]
11. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
Martínez-Martín P; Hernández B; Ricart J;
Neurologia; 2014 Apr; 29(3):153-60. PubMed ID: 23465686
[TBL] [Abstract][Full Text] [Related]
12. [The estimation of prevalence of Parkinson disease in Navarra. An epidemiological study of the consumption of anti-parkinsonian drugs].
Artázcoz Sanz MT; Viñes Rueda JJ
Rev Esp Salud Publica; 1995; 69(6):479-85. PubMed ID: 8789360
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data.
Davis KL; Edin HM; Allen JK
Mov Disord; 2010 Mar; 25(4):474-80. PubMed ID: 20131374
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Parkinson's disease and other types of Parkinsonism. A door-to-door survey in Bidasoa, Spain.
Bergareche A; De La Puente E; López de Munain A; Sarasqueta C; de Arce A; Poza JJ; Martí-Massó JF
J Neurol; 2004 Mar; 251(3):340-5. PubMed ID: 15015016
[TBL] [Abstract][Full Text] [Related]
15. [Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy].
Dodel RC; Pepperl S; Köhne-Volland R; Szucs T; Werhahn KJ; Noachtar S; Oertel WH
Med Klin (Munich); 1996 Jul; 91(7):479-85. PubMed ID: 8756119
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of parkinsonism and Parkinson's disease in the Arosa Island (Spain): a community-based door-to-door survey.
Seijo-Martinez M; Castro del Rio M; Rodríguez Alvarez J; Suarez Prado R; Torres Salgado E; Paz Esquete J; Sobrido MJ
J Neurol Sci; 2011 May; 304(1-2):49-54. PubMed ID: 21402385
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model.
Davey P; Rajan N; Lees M; Aristides M
Value Health; 2001; 4(4):308-15. PubMed ID: 11705298
[TBL] [Abstract][Full Text] [Related]
18. Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study.
Valldeoriola F; Puig-Junoy J; Puig-Peiró R;
J Med Econ; 2013; 16(2):191-201. PubMed ID: 23035627
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Parkinson's disease in Cantalejo, Spain: a door-to-door survey.
Clavería LE; Duarte J; Sevillano MD; Pérez-Sempere A; Cabezas C; Rodríguez F; de Pedro-Cuesta J
Mov Disord; 2002 Mar; 17(2):242-9. PubMed ID: 11921108
[TBL] [Abstract][Full Text] [Related]
20. Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambuí study).
Barbosa MT; Caramelli P; Maia DP; Cunningham MC; Guerra HL; Lima-Costa MF; Cardoso F
Mov Disord; 2006 Jun; 21(6):800-8. PubMed ID: 16482566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
